Levosulpiride

DB16021

small molecule experimental

Deskripsi

Struktur Molekul 2D

Berat 341.43
Wujud -

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

689 Data
Buprenorphine Levosulpiride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levosulpiride.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Levosulpiride.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Levosulpiride.
Hydrocodone Levosulpiride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Levosulpiride.
Magnesium sulfate The therapeutic efficacy of Levosulpiride can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Levosulpiride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Levosulpiride may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Levosulpiride.
Mirtazapine Levosulpiride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Levosulpiride.
Orphenadrine Levosulpiride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Levosulpiride may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Levosulpiride.
Pramipexole Levosulpiride may increase the sedative activities of Pramipexole.
Ropinirole Levosulpiride may increase the sedative activities of Ropinirole.
Rotigotine Levosulpiride may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Levosulpiride.
Sodium oxybate Levosulpiride may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Levosulpiride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Levosulpiride.
Thalidomide Levosulpiride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Levosulpiride may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Amisulpride Levosulpiride may increase the antipsychotic activities of Amisulpride.
Methylphenidate The risk or severity of adverse effects can be increased when Levosulpiride is combined with Methylphenidate.
Dexmethylphenidate The risk or severity of adverse effects can be increased when Levosulpiride is combined with Dexmethylphenidate.
Metoclopramide The risk or severity of adverse effects can be increased when Metoclopramide is combined with Levosulpiride.
Quinagolide The therapeutic efficacy of Quinagolide can be decreased when used in combination with Levosulpiride.
Sulpiride Levosulpiride may increase the antipsychotic activities of Sulpiride.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Levosulpiride.
Lithium hydroxide Lithium hydroxide may increase the neurotoxic activities of Levosulpiride.
Lithium citrate Lithium citrate may increase the neurotoxic activities of Levosulpiride.
Lithium carbonate Lithium carbonate may increase the neurotoxic activities of Levosulpiride.
Mequitazine Levosulpiride may increase the arrhythmogenic activities of Mequitazine.
Tetrabenazine The risk or severity of adverse effects can be increased when Levosulpiride is combined with Tetrabenazine.
Deutetrabenazine The risk or severity of adverse effects can be increased when Levosulpiride is combined with Deutetrabenazine.
Ethanol Levosulpiride may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Levosulpiride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Levosulpiride.
Fluvoxamine The risk or severity of adverse effects can be increased when Levosulpiride is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Levosulpiride is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Levosulpiride is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Levosulpiride is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Levosulpiride is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Levosulpiride is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Levosulpiride is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Levosulpiride is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Levosulpiride is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Levosulpiride is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Levosulpiride is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Levosulpiride is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Levosulpiride is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Levosulpiride is combined with Seproxetine.
Levomilnacipran The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Levosulpiride.
Indalpine The risk or severity of adverse effects can be increased when Levosulpiride is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Levosulpiride is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Levosulpiride is combined with Alaproclate.
Amitriptyline The risk or severity of adverse effects can be increased when Amitriptyline is combined with Levosulpiride.
Olanzapine The risk or severity of CNS depression can be increased when Olanzapine is combined with Levosulpiride.
Clozapine The risk or severity of CNS depression can be increased when Clozapine is combined with Levosulpiride.
Promazine The risk or severity of CNS depression can be increased when Promazine is combined with Levosulpiride.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Levosulpiride.
Imipramine The risk or severity of adverse effects can be increased when Imipramine is combined with Levosulpiride.
Chlorpromazine The risk or severity of CNS depression can be increased when Chlorpromazine is combined with Levosulpiride.
Gallamine triethiodide The risk or severity of CNS depression can be increased when Gallamine triethiodide is combined with Levosulpiride.
Triflupromazine The risk or severity of CNS depression can be increased when Triflupromazine is combined with Levosulpiride.
Nortriptyline The risk or severity of adverse effects can be increased when Nortriptyline is combined with Levosulpiride.
Amoxapine The risk or severity of adverse effects can be increased when Amoxapine is combined with Levosulpiride.
Lamotrigine The risk or severity of CNS depression can be increased when Lamotrigine is combined with Levosulpiride.
Rocuronium The risk or severity of CNS depression can be increased when Rocuronium is combined with Levosulpiride.
Scopolamine The risk or severity of CNS depression can be increased when Scopolamine is combined with Levosulpiride.
Clidinium The risk or severity of CNS depression can be increased when Clidinium is combined with Levosulpiride.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Levosulpiride.
Brompheniramine The risk or severity of CNS depression can be increased when Brompheniramine is combined with Levosulpiride.
Flupentixol The risk or severity of CNS depression can be increased when Flupentixol is combined with Levosulpiride.
Maprotiline The risk or severity of adverse effects can be increased when Maprotiline is combined with Levosulpiride.
Promethazine The risk or severity of adverse effects can be increased when Promethazine is combined with Levosulpiride.
Diphenhydramine The risk or severity of CNS depression can be increased when Diphenhydramine is combined with Levosulpiride.
Doxacurium The risk or severity of CNS depression can be increased when Doxacurium is combined with Levosulpiride.
Doxepin The risk or severity of adverse effects can be increased when Doxepin is combined with Levosulpiride.
Desipramine The risk or severity of adverse effects can be increased when Desipramine is combined with Levosulpiride.
Quetiapine The risk or severity of CNS depression can be increased when Quetiapine is combined with Levosulpiride.
Mivacurium The risk or severity of CNS depression can be increased when Mivacurium is combined with Levosulpiride.
Aripiprazole The risk or severity of CNS depression can be increased when Aripiprazole is combined with Levosulpiride.
Chlorprothixene The risk or severity of CNS depression can be increased when Chlorprothixene is combined with Levosulpiride.
Metocurine The risk or severity of CNS depression can be increased when Metocurine is combined with Levosulpiride.
Pancuronium The risk or severity of CNS depression can be increased when Pancuronium is combined with Levosulpiride.
Pipecuronium The risk or severity of CNS depression can be increased when Pipecuronium is combined with Levosulpiride.
Rapacuronium The risk or severity of CNS depression can be increased when Rapacuronium is combined with Levosulpiride.
Pizotifen The risk or severity of CNS depression can be increased when Pizotifen is combined with Levosulpiride.
Benactyzine The risk or severity of CNS depression can be increased when Benactyzine is combined with Levosulpiride.
Dosulepin The risk or severity of adverse effects can be increased when Dosulepin is combined with Levosulpiride.
Emepronium The risk or severity of CNS depression can be increased when Emepronium is combined with Levosulpiride.
Zopiclone The risk or severity of adverse effects can be increased when Levosulpiride is combined with Zopiclone.
Eletriptan The risk or severity of adverse effects can be increased when Eletriptan is combined with Levosulpiride.
Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Levosulpiride.
Venlafaxine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Levosulpiride.
Zolmitriptan The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Levosulpiride.
Dihydroergotamine The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Levosulpiride.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul